 |
||||||||
 |
 |
 |
 |
 |
||||
 |
||||||||
 |
 |
 |
 |
 |
||||
 |
|
|
|
|
|
|
|
|
Dear RATLAS user The link to RATLAS has been moved from http://mr.imaging-ks.nu/expmr.htm for technical reasons. RATLAS can now be downloaded here. Journal of Neuroscience Methods Volume 129, Issue 2 30 October 2003, Pages 105-113 A template for spatial normalisation of MR images of the rat brain Petra Schweinhardt, Peter Fransson, Lars Olson, Christian Spenger* and Jesper L. R. Andersson; Corresponding Author: Christian Spenger Medical Imaging Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Schou M, Steiger C, Varrone A, Guilloteau D, Halldin C. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4843-5. Epub 2009 Jun 13. Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[(18)F]FMeNER-D (2) and (S,S)-[ (11)C]MeNER. Takano A, Gulyás B, Varrone A, Halldin C. Eur J Nucl Med Mol Imaging. 2009 Jun 30. Modulation of striatal dopamine D1 binding by cognitive processing. Karlsson S, Nyberg L, Karlsson P, Fischer H, Thilers P, Macdonald S, Brehmer Y, Rieckmann A, Halldin C, Farde L, Bäckman L. Neuroimage. 2009 Nov 1;48(2):398-404. Epub 2009 Jun 17. Detection of amyloid in Alzheimer's disease with positron emission tomography using [(11)C]AZD2184. Nyberg S, Jönhagen ME, Cselényi Z, Halldin C, Julin P, Olsson H, Freund-Levi Y, Andersson J, Varnäs K, Svensson S, Farde L. Eur J Nucl Med Mol Imaging. 2009 Jun 5. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Varrone A, Sjöholm N, Eriksson L, Gulyás B, Halldin C, Farde L. Eur J Nucl Med Mol Imaging. 2009 May 13. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain. Otsuka T, Ito H, Halldin C, Takahashi H, Takano H, Arakawa R, Okumura M, Kodaka F, Miyoshi M, Sekine M, Seki C, Nakao R, Suzuki K, Finnema S, Hirayasu Y, Suhara T, Farde L. J Nucl Med. 2009 May;50(5):703-10. Epub 2009 Apr 16. Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. Tokunaga M, Seneca N, Shin RM, Maeda J, Obayashi S, Okauchi T, Nagai Y, Zhang MR, Nakao R, Ito H, Innis RB, Halldin C, Suzuki K, Higuchi M, Suhara T. J Neurosci. 2009 Feb 11;29(6):1887-96. [18F]flumazenil binding to central benzodiazepine receptor studies by PET--quantitative analysis and comparisons with [11C]flumazenil. Odano I, Halldin C, Karlsson P, Varrone A, Airaksinen AJ, Krasikova RN, Farde L. Neuroimage. 2009 Apr 15;45(3):891-902. Epub 2008 Dec 24. 5-HT(1A) receptor and 5-HTT binding during the menstrual cycle in healthy women examined with [(11)C] WAY100635 and [(11)C] MADAM PET. Jovanovic H, Karlsson P, Cerin A, Halldin C, Nordström AL. Psychiatry Res. 2009 Apr 30;172(1):31-7. Epub 2009 Jan 1. In-target produced [11C]methane: Increased specific radioactivity. Andersson J, Truong P, Halldin C. Appl Radiat Isot. 2009 Jan;67(1):106-10. Epub 2008 Oct 5. Investigation of the metabolites of (S,S)-[(11)C]MeNER in humans, monkeys and rats. Schou M, Zoghbi SS, Shetty HU, Shchukin E, Liow JS, Hong J, Andrée BA, Gulyás B, Farde L, Innis RB, Pike VW, Halldin C. Mol Imaging Biol. 2009 Jan-Feb;11(1):23-30. Epub 2008 Sep 18. A fully automated one-pot synthesis of [carbonyl-11C]WAY-100635 for clinical PET applications. Krasikova RN, Andersson J, Truong P, Nag S, Shchukin EV, Halldin C. Appl Radiat Isot. 2009 Jan;67(1):73-8. Epub 2008 Jul 22. Biomarker Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. Schneider P, Hampel H, Buerger K. CNS Neurosci Ther. 2009 Oct 14. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Exp Neurol. 2009 Oct 6. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Ewers M, Mielke MM, Hampel H. Exp Gerontol. 2009 Sep 24. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H. Exp Gerontol. 2009 Sep;44(9):579-85. Epub 2009 Jun 16. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. Hampel H, Broich K. J Nutr Health Aging. 2009 Apr;13(4):373-5. Ultrasound Comeing soon Medical Image Analysis Comeing soon |
ISO 9001 |
Contact us by phone: +41 (0) 71 913 05 80, by mail: info (at) prodemamedical.com
Copyright © 2009 Prodema Medical